BeiGene Discontinues Lung Cancer Drug Study After Interim Data Showed Limited Survival Benefit

BeiGene Ltd (NASDAQ:ONC) on Thursday announced the discontinuation of its clinical development program for ociperlimab (BGB-A1217), an anti-TIGIT antibody, as a potential treatment for lung cancer.

The Independent Data Monitoring Committee recommended terminating the ongoing Phase 3 AdvanTIG-302 trial based on its findings as part of a pre-planned futility analysis.

Also Read: China-Based Biotech BeiGene Scores FDA Approval For Tevimbra/Chemo Combo For ...

https://www.benzinga.com/general/biotech/25/04/44630279/beigene-discontinues-lung-cancer-drug-study-after-interim-data-showed-limited-survival-benefit